TY - JOUR
T1 - New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide
AU - Boxtel, W.
AU - Bulten, Ben
AU - Mavinkurve-Groothuis, A.M.
AU - Bellersen, L.
AU - Mandigers, C.M.
AU - Joosten, L.A.
AU - Kapusta, L.
AU - de Geus-Oei, Lioe-Fee
AU - van Laarhoven, H.W.
PY - 2015
Y1 - 2015
N2 - Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines.
Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines.
Results: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01).
Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
AB - Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines.
Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines.
Results: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01).
Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
KW - n/a OA procedure
U2 - 10.3109/1354750X.2015.1040839
DO - 10.3109/1354750X.2015.1040839
M3 - Article
SN - 1354-750X
VL - 20
SP - 143
EP - 148
JO - Biomarkers
JF - Biomarkers
IS - 2
ER -
